AbbVie (ABBV) financial statements
+250.6%since 2011
- FY2025 revenue
- $61.2B▲ +8.6%
- FY2025 net income
- $4.2B▼ −1.2%
- FY2025 diluted EPS
- $2.36▼ −1.3%
- FY2025 free cash flow
- $17.8B▼ −0.1%
AbbVie income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 61,160 | 56,334 | 54,318 |
| Operating income | 15,075 | 9,137 | 12,757 |
| Pretax income | 6,597 | 3,716 | 6,250 |
| Net income | 4,226 | 4,278 | 4,863 |
| Diluted earnings per share | 2.36 | 2.39 | 2.72 |
AbbVie balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 5,229 | 5,524 | 12,814 |
| Total assets | 133,960 | 135,161 | 134,711 |
| Total liabilities (derived) | 137,188 | 131,797 | 124,314 |
| Total equity | -3,228 | 3,364 | 10,397 |
| Long-term debt | 58,941 | 60,340 | 52,194 |
AbbVie cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 19,030 | 18,806 | 22,839 |
| Capital expenditure | -1,214 | -974 | -777 |
| Free cash flow (derived) | 17,816 | 17,832 | 22,062 |
| Dividends paid | -11,657 | -11,025 | -10,539 |
| Share repurchases | -980 | -1,708 | -1,972 |
Quarterly highlights
| USD millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue | 17,404 | 16,990 | 15,002 | 16,618 |
| Operating income (derived) | 6,267 | 6,432 | 3,990 | 4,544 |
| Net income | 4,218 | 3,613 | 695 | 1,816 |
| Diluted earnings per share | 2.37 | 2.03 | 0.39 | 1.02 |
| Operating cash flow (derived) | 7,606 | 3,436 | 3,829 | 5,218 |
| Total assets | 147,680 | 135,115 | 136,463 | 133,960 |
AbbVie major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| Vanguard Capital Management | 7.5% | 132,924,058 | 30 April 2026 |
AbbVie 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 3 November 2026 | 10-Q | Quarterly report | Quarterly report |
| 2 November 2026 | 8-K | Current report | FORM 8-K |
| 30 October 2026 | 8-K | Current report | Current report |
| 15 October 2026 | 8-K | Current report | FORM 8-K |
| 5 October 2026 | 8-K | Current report | Current report |
| 3 September 2026 | 8-K | Current report | FORM 8-K |
| 18 August 2026 | 8-K | Current report | FORM 8-K |
| 5 August 2026 | 8-K | Current report | FORM 8-K |
Common questions
What was AbbVie's revenue in fiscal 2025?
AbbVie reported $61.2 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 8.6% from fiscal 2024.
What was AbbVie's net income in fiscal 2025?
AbbVie reported net income of $4.2 billion for fiscal 2025, the year ended 31 December 2025, down 1.2% from fiscal 2024. Diluted earnings per share were $2.36.
What was AbbVie's free cash flow in fiscal 2025?
AbbVie had $17.8 billion in free cash flow in fiscal 2025. Operating cash flow was $19.0 billion and capital expenditure was $1.2 billion.
What were AbbVie's total assets at the end of fiscal 2025?
AbbVie reported total assets of $134.0 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much AbbVie history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.